1. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 
F. Canducci, B. Barda, E. Ceresola, V. Spagnuolo, M. Sampaolo, E. Boeri, S. Nozza, F. Cossarin, A. Galli, N. Gianotti, A. Castagna, A. Lazzarin, M. Clementi 
Clinical Microbiology and Infection 
Volume 17, Issue 6, Pages (June 2011)
DOI: /j x
Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions

2. FIG. 1
Virological and immunological parameters of the patients described in the study and patients’ therapies. AZT, zidovudine; FTC, emtricitabine; TdF, tenofovir; RAL, raltegravir; ETR, etravirine; 3TC, lamivudine; DRV, darunavir; ENF, enfuvirtide; MVC, maraviroc; ABC, abacavir; f-APV, fosamprenavir; LPV/r, lopinavir/ritonavir; DRV/r, darunavir/ritonavir; TPVr, tipranavir/ritonavir.
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions